GSC
KZIA

Ground Swell Capital’s Kazia Therapeutics KZIA Stock Holding History

Ground Swell Capital’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-223
Closed -$3.51K – 199
2024
Q1 		$3.51K Buy
+223
New +$3.34K ﹤0.01% 70

Other funds holding KZIA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return

Ground Swell Capital's KZIA Position: Q2 2024 in Review

Ground Swell Capital sold out of Kazia Therapeutics (KZIA) in Q2 2024, closing a stake of 223 shares — an estimated $3.51K sold.

Ground Swell Capital first reported a position in KZIA in Q1 2024 and held it in 1 quarter. The position peaked at $3.51K in Q1 2024. 9 funds tracked by Wall St. Rank hold KZIA as of Q2 2024.

  • Ground Swell Capital reported no remaining Kazia Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Ground Swell Capital sold 223 Kazia Therapeutics shares in Q2 2024, an estimated $3.51K.
  • Ground Swell Capital first reported a position in Kazia Therapeutics in Q1 2024 and held it in 1 quarter.
  • Ground Swell Capital's Kazia Therapeutics position peaked at $3.51K in Q1 2024.
  • 9 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q2 2024.

Based on Ground Swell Capital's 13F filing for Q2 2024, filed 7 Aug 2024.